Candel Therapeutics, Inc. (CADL)

Candel Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	119.73	102.65	35.41	70.06	82.64
Cash & Short-Term Investments	119.73	102.65	35.41	70.06	82.64
Cash Growth	16.63%	189.88%	-49.45%	-15.23%	135.76%
Other Current Assets	1.66	1.15	1.38	1.89	2.3
Total Current Assets	121.39	103.8	36.8	71.95	84.95
Net Property, Plant & Equipment	3.3	2.73	4.02	5.48	3.84
Other Long-Term Assets	0.5	0.33	0.38	0.27	0.42
Total Assets	125.2	106.87	41.2	77.69	89.21
Accounts Payable	1.13	0.24	0.42	0.38	1.59
Accrued Expenses	7.33	5.11	4.36	4.72	3.44
Current Portion of Long-Term Debt	-	9.9	8.89	-	-
Current Portion of Leases	0.45	0.57	0.51	0.46	-
Other Current Liabilities	0.09	21.72	-	0.05	0.33
Total Current Liabilities	9	37.53	14.18	5.62	5.36
Long-Term Debt	47.13	2.6	12.38	20.85	0.56
Long-Term Leases	1.46	0.41	0.97	1.49	-
Other Long-Term Liabilities	15.69	-	0.92	2.03	19.15
Total Long-Term Liabilities	64.28	3.01	14.27	24.36	19.71
Total Liabilities	73.27	40.54	28.46	29.98	25.07
Common Stock	0.55	0.47	0.29	0.29	0.29
Treasury Stock	-0.45	-0.45	-0.45	-0.45	-
Additional Paid-in Capital	282.21	258.51	149.93	146.96	144.15
Retained Earnings	-230.39	-192.21	-137.03	-99.09	-80.3
Shareholders' Equity	51.92	66.33	12.75	47.71	64.14
Total Liabilities & Equity	125.2	106.87	41.2	77.69	89.21
Total Debt	49.03	13.47	22.76	22.8	0.56
Net Cash (Debt)	70.7	89.18	12.65	47.26	82.08
Net Cash Growth	-20.73%	604.95%	-73.23%	-42.43%	140.66%
Net Cash Per Share	1.33	2.82	0.44	1.64	4.35
Book Value	51.92	66.33	12.75	47.71	64.14
Book Value Per Share	0.98	2.09	0.44	1.66	3.40
Tangible Book Value	51.92	66.33	12.75	47.71	64.14
Tangible Book Value Per Share	0.98	2.09	0.44	1.66	3.40

Updated Mar 12, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q